Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis

Effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) in relapsing–remitting multiple sclerosis (MS) is well known, but in secondary–progressive (SP)‐MS it is still controversial. Therefore, AHSCT activity was evaluated in SP‐MS using low‐dose immunosuppression with cyclophosphamide (Cy) as a comparative treatment.

[1]  J. Burman.  Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile? , 2021, Multiple Sclerosis and Related Disorders.

[2]  M. Sormani,et al.  Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis , 2021, Neurology.

[3]  J. Flores-Rivera,et al.  Cyclophosphamide treatment in active multiple sclerosis , 2021, Neurological Sciences.

[4]  G. Carlucci,et al.  Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis , 2020, Multiple sclerosis.

[5]  D. Reich,et al.  Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. , 2019, JAMA neurology.

[6]  M. Sormani,et al.  Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) , 2019, Bone Marrow Transplantation.

[7]  B. Sharrack,et al.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial , 2019, JAMA.

[8]  H. Lassmann.  Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..

[9]  C. Lebrun,et al.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs , 2018, CNS Drugs.

[10]  A. Cross,et al.  Disease-Modifying Treatment in Progressive Multiple Sclerosis , 2018, Current Treatment Options in Neurology.

[11]  Ludwig Kappos,et al.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study , 2018, The Lancet.

[12]  H. Atkins,et al.  Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis , 2017, JAMA neurology.

[13]  P. Vermersch,et al.  Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis , 2017, PloS one.

[14]  D. Arnold,et al.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial , 2016, The Lancet.

[15]  Céline Louapre,et al.  Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes , 2015, Multiple sclerosis.

[16]  Istvan Pirko,et al.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque , 2015, Annals of neurology.

[17]  M. Hutchinson.  Neurodegeneration in multiple sclerosis is a process separate from inflammation: No , 2015, Multiple sclerosis.

[18]  D. Fedorenko,et al.  Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives , 2015, Annals of Hematology.

[19]  Paul R. Rosenbaum,et al.  Matching for Balance, Pairing for Heterogeneity in an Observational Study of the Effectiveness of For-Profit and Not-For-Profit High Schools in Chile , 2014, 1404.3584.

[20]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[21]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[22]  W. Hwang,et al.  Autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. , 2007, Annals of the Academy of Medicine, Singapore.

[23]  K. Hynynen,et al.  Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Rubin.  The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials , 2007, Statistics in medicine.

[25]  M. Calabrese,et al.  Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis , 2006, Journal of Neurology.

[26]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[27]  P. Vermersch,et al.  Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients , 2004, Journal of the Neurological Sciences.

[28]  B. Cohen,et al.  Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. , 2003, Blood.

[29]  P. Gallo,et al.  Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis , 2003, Journal of Neurology.

[30]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[31]  T. A. S. Group.  The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis , 1991, The Lancet.

[32]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[33]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[34]  M. Salcman,et al.  Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide , 1982, Clinical pharmacology and therapeutics.